Shopping Cart 0
Cart Subtotal
AED 0

Ampio Pharmaceuticals Inc (AMPE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level. It provides products for the treatment of osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases. Ampio's products include low molecular weight fraction of human serum albumin and ultra-low dose of danazol. Its ultra-low dose of danazol is used for the oral treatment of diabetic macular edema. The company conducts research on various future indications for optina. It partners with other biopharmaceutical companies for its research activities. Ampio is headquartered in Englewood, Colorado, the US.

Ampio Pharmaceuticals Inc (AMPE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ampio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Merger 11

Rosewind Merges with Vyrix Pharma and Luoxis Diagnostics in Reverse Merger Transaction 11

Licensing Agreements 12

FBM FARMA Industria Farmaceutica Enters Into Licensing Agreement With Ampio Pharma For Zertane 12

Equity Offering 13

Ampio Pharma Prices Public Offering of Shares and Warrants for USD8 Million 13

Ampio Pharma Raises USD6.7 Million Private Placement of Shares 14

Ampio Pharma Raises USD6.6 Million in Private Placement of Shares and Warrants 15

Ampio Pharma Raises USD3.8 Million in Private Placement of Shares and Warrants 17

Ampio Pharma Raises up to USD25 Million in Public Offering of Shares 19

Aytu BioScience Spin-Off from Ampio Pharma 20

Ampio Pharma Completes Public Offering Of Shares For USD 68.4 Million 21

Ampio Pharma Completes Private Placement Of Shares For USD 25.3 Million 22

Ampio Pharma Completes First Tranche Of Private Placement Of Shares 23

Ampio Pharma Completes Public Offering Of Shares For USD 17 Million 24

Ampio Pharmaceuticals Inc-Key Competitors 25

Ampio Pharmaceuticals Inc-Key Employees 26

Ampio Pharmaceuticals Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Nov 16, 2017: Ampio Pharmaceuticals Announces Continued Listing Plan Accepted by NYSE American 28

Jun 12, 2017: Ampio Announces Appointment of Interim Chief Financial Officer 29

Other Significant Developments 30

May 14, 2018: Ampio Provides Corporate Update 30

Mar 15, 2018: Ampio Pharmaceuticals Provides Corporate Update Following Conference Call 31

Mar 20, 2017: Ampio Pharmaceuticals Provides Corporate Update 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ampio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ampio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Ampio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rosewind Merges with Vyrix Pharma and Luoxis Diagnostics in Reverse Merger Transaction 11

FBM FARMA Industria Farmaceutica Enters Into Licensing Agreement With Ampio Pharma For Zertane 12

Ampio Pharma Prices Public Offering of Shares and Warrants for USD8 Million 13

Ampio Pharma Raises USD6.7 Million Private Placement of Shares 14

Ampio Pharma Raises USD6.6 Million in Private Placement of Shares and Warrants 15

Ampio Pharma Raises USD3.8 Million in Private Placement of Shares and Warrants 17

Ampio Pharma Raises up to USD25 Million in Public Offering of Shares 19

Aytu BioScience Spin-Off from Ampio Pharma 20

Ampio Pharma Completes Public Offering Of Shares For USD 68.4 Million 21

Ampio Pharma Completes Private Placement Of Shares For USD 25.3 Million 22

Ampio Pharma Completes First Tranche Of Private Placement Of Shares 23

Ampio Pharma Completes Public Offering Of Shares For USD 17 Million 24

Ampio Pharmaceuticals Inc, Key Competitors 25

Ampio Pharmaceuticals Inc, Key Employees 26

Ampio Pharmaceuticals Inc, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ampio Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level. It provides products for the treatment of osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases. Ampio's products include low molecular weight fraction of human serum albumin and ultra-low dose of danazol. Its ultra-low dose of danazol is used for the oral treatment of diabetic macular edema. The company conducts research on various future indications for optina. It partners with other biopharmaceutical companies for its research activities. Ampio is headquartered in Englewood, Colorado, the US.

Ampio Pharmaceuticals Inc (AMPE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ampio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Merger 11

Rosewind Merges with Vyrix Pharma and Luoxis Diagnostics in Reverse Merger Transaction 11

Licensing Agreements 12

FBM FARMA Industria Farmaceutica Enters Into Licensing Agreement With Ampio Pharma For Zertane 12

Equity Offering 13

Ampio Pharma Prices Public Offering of Shares and Warrants for USD8 Million 13

Ampio Pharma Raises USD6.7 Million Private Placement of Shares 14

Ampio Pharma Raises USD6.6 Million in Private Placement of Shares and Warrants 15

Ampio Pharma Raises USD3.8 Million in Private Placement of Shares and Warrants 17

Ampio Pharma Raises up to USD25 Million in Public Offering of Shares 19

Aytu BioScience Spin-Off from Ampio Pharma 20

Ampio Pharma Completes Public Offering Of Shares For USD 68.4 Million 21

Ampio Pharma Completes Private Placement Of Shares For USD 25.3 Million 22

Ampio Pharma Completes First Tranche Of Private Placement Of Shares 23

Ampio Pharma Completes Public Offering Of Shares For USD 17 Million 24

Ampio Pharmaceuticals Inc-Key Competitors 25

Ampio Pharmaceuticals Inc-Key Employees 26

Ampio Pharmaceuticals Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Nov 16, 2017: Ampio Pharmaceuticals Announces Continued Listing Plan Accepted by NYSE American 28

Jun 12, 2017: Ampio Announces Appointment of Interim Chief Financial Officer 29

Other Significant Developments 30

May 14, 2018: Ampio Provides Corporate Update 30

Mar 15, 2018: Ampio Pharmaceuticals Provides Corporate Update Following Conference Call 31

Mar 20, 2017: Ampio Pharmaceuticals Provides Corporate Update 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Ampio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Ampio Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Ampio Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Ampio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Rosewind Merges with Vyrix Pharma and Luoxis Diagnostics in Reverse Merger Transaction 11

FBM FARMA Industria Farmaceutica Enters Into Licensing Agreement With Ampio Pharma For Zertane 12

Ampio Pharma Prices Public Offering of Shares and Warrants for USD8 Million 13

Ampio Pharma Raises USD6.7 Million Private Placement of Shares 14

Ampio Pharma Raises USD6.6 Million in Private Placement of Shares and Warrants 15

Ampio Pharma Raises USD3.8 Million in Private Placement of Shares and Warrants 17

Ampio Pharma Raises up to USD25 Million in Public Offering of Shares 19

Aytu BioScience Spin-Off from Ampio Pharma 20

Ampio Pharma Completes Public Offering Of Shares For USD 68.4 Million 21

Ampio Pharma Completes Private Placement Of Shares For USD 25.3 Million 22

Ampio Pharma Completes First Tranche Of Private Placement Of Shares 23

Ampio Pharma Completes Public Offering Of Shares For USD 17 Million 24

Ampio Pharmaceuticals Inc, Key Competitors 25

Ampio Pharmaceuticals Inc, Key Employees 26

Ampio Pharmaceuticals Inc, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ampio Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.